Hilden, Germany, and Germantown, Maryland, September 08, 2020 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a rapid portable test that can detect SARS-CoV-2 antigens in people with active infections in less than 15 minutes and process on average around 30 swab samples per hour using a small digital detection... Read more
Hilden, 8. September 2020 – QIAGEN hat heute angekündigt, mehr als 110 Mio. Euro in den Ausbau seiner Kapazitäten für die Fertigung von COVID-19-Testprodukten an den Standorten Hilden, Germantown (Maryland, USA) und Barcelona zu investieren. Mit dem bislang größten Investitionsprogramm in der Unternehmensgeschichte setzt QIAGEN seine Anstrengungen fort, den globalen Kampf gegen die Pandemie durch die Erhöhung von... Read more
CAMBRIDGE, Inglaterra–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) ha anunciado hoy una colaboración con 54gene, una empresa de tecnología sanitaria cuya misión es hacer avanzar las capacidades de la medicina de precisión en África a través de la investigación, los diagnósticos moleculares avanzados y los programas clínicos. La asociación ayudará a la creación de una nueva instalación... Read more
CAMBRIDGE, England–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) gab heute eine Zusammenarbeit mit 54gene bekannt, einem Unternehmen der Gesundheitstechnologie, dessen Aufgabe es ist, die Fähigkeiten der Präzisionsmedizin in Afrika durch Forschung, fortschrittliche molekulare Diagnostik und klinische Programme zu fördern. Die Partnerschaft wird die Einrichtung einer neuen Genetik-Einrichtung in Lagos, Nigeria, unterstützen, die mit einer Reihe von Illuminas... Read more
CAMBRIDGE, Inghilterra–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) ha annunciato oggi una collaborazione con 54gene, società operante nel campo delle tecnologie sanitarie la cui missione è promuovere le competenze della medicina di precisione in Africa attraverso ricerca, diagnostica molecolare avanzata e programmi clinici. La partnership sosterrà la creazione di un nuovo centro di genetica a Lagos, in... Read more
CAMBRIDGE, Engeland–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) kondigde vandaag een samenwerking aan met 54gene, een gezondheidstechnologiebedrijf dat tot doel heeft de capaciteiten van precisiegeneeskunde in Afrika te vergroten door middel van onderzoek, geavanceerde moleculaire diagnostiek en klinische programma’s. Het partnerschap ondersteunt de oprichting van een nieuwe genetica-faciliteit in Lagos, Nigeria, uitgerust met een reeks van Illumina’s... Read more
Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status Affordable and small, instrument-free testing kit enables convenient use for healthcare professionals at different point of... Read more
Critical Care Suite helps radiologists prioritize critical cases with a suspected pneumothorax – a type of collapsed lung – by immediately flagging critical cases to radiologists for triage, which could drastically cut the average review time from up to eight hours[1] Offers first-of-its-kind automated AI quality check features that detect acquisition errors, flagging images for... Read more
| CDX Installation Profile Skip to main content Drupal already installed To start over, you must empty your existing database and copy default.settings.php over settings.php. To upgrade an existing installation, proceed to the update script. View your existing site. http://www.genewsroom.com/feeds/healthcare.rss.xml Read more
REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. The companies will collaborate on developing and manufacturing REGN-COV2. Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S. Under this collaboration, the overall capacity of REGN-COV2 is expected to... Read more